The ABC subtype (~30% of DLBCL patients) is driven by MyD88 gain-of-function mutation that results in constitutive activation and depends upon IRAK1- and IRAK4-mediated signaling for survival [167]. This evidence concerns the gene MYD88 and aneurysmal bone cyst.